▶Most common skin disease that is treated by physicians.
▶Affects approximately 45 million individuals in the United States, including at least 85% of all teenagers and young adults.
▶Most often self-limited and tends to remit during early adulthood, but can be a continuing problem for a significant subset of young and middle-aged adults.
▶Has the potential for significant negative effect on quality of life.
▶Successful treatment is generally associated with improved psychologic well-being.
Pathophysiology
▶Result of a complex interaction between hormonal changes and their effects on the pilosebaceous apparatus (ie, specialized structures consisting of a hair follicle and sebaceous gland s concentrated on the face, chest, and back).
▶Onset at puberty as a result of increased and rogen production.
▶End-organ and rogen hyperresponsiveness of the follicle probably also plays a role.
▶Disordered function of the pilosebaceous unit with abnormal follicular keratinization (tendency toward increased follicular plugging).
▶Increased sebum production, under the influence of adrenal and gonadal and rogens.
▶Cutibacterium (formerly Propionibacterium) acnes likely contributes to the pathogenesis of acne via activation of the innate immune response via toll-like receptors, although this relationship continues to be explored.
Factors That May Exacerbate Acne
▶Trauma: scrubbing the skin too vigorously or picking of lesions.
▶Comedogenic cosmetics or other skin care products.
▶Tight-fitting sports equipment.
▶Medications: corticosteroids (topical, inhaled, and oral) and anabolic steroids, antiepileptic drugs, lithium, and certain contraceptives.
▶Hormonal dysregulation as occurs with polycystic ovarian syndrome and Cushing syndrome (may be associated with more severe acne). Hormonal contraception with progesterone only (eg, progesterone-only minipill, progesterone intrauterine device, implantable progesterone) may worsen acne.
▶A high glycemic index diet and consumption of nonfat dairy may be associated with acne vulgaris.
Early on, acne lesions often appear on the forehead and middle third of the face (T-zone) and are obstructive (ie, comedones); inflammatory lesions tend to develop later and may occur on all areas of the face, neck, chest, and back.
▶Comedonal lesions: often the first sign of acne, appearing before other signs of puberty.
■Open comedones (blackheads): dilated follicles (Figure 7.1).
■Closed comedones (whiteheads): white or skin-colored papules without surrounding erythema (Figure 7.2).
■Recent data suggest these lesions may be accompanied by inflammation, although it is not clinically apparent.
▶Inflammatory lesions typically appear later in the course of acne vulgaris and vary from 1- to 2-mm micro-papules to nodules larger than 5 mm (Figure 7.3).
▶Large (5–15 mm) inflammatory nodules and cysts occur in the most severe cases, and such nodulocystic presentations are most likely to lead to permanent scarring.
■Mild, moderate, and severe inflammatory acne can be associated with disfiguring postinflammatory discoloration, which can be red, violaceous, or gray-brown hyperpigmentation.
■Pigmentary changes may persist for many months to years (Figure 7.4).
Look-alikes
In each of the conditions listed herein, comedones are absent.
Disorder | Differentiating Features |
Acne rosacea | •Flushing and telangiectasias |
Angiofibromas (ie, adenoma sebaceum) | •Appears during childhood (earlier than acne) •Favors nose and medial cheeks •Associated with tuberous sclerosis or multiple endocrine neoplasia type 1 |
•Skin-colored to tan papules or small, thin plaques •Koebnerization (lesions distributed in linear clusters) often present | |
•Sudden worsening of acne in patient receiving long-term antibiotic treatment for acne vulgaris | |
•Presents during infancy or early childhood. •Presence of a central keratin plug differentiates keratosis pilaris from acne. •Favors lateral cheeks (rather than T-zone) and may also be present on the extensor upper arms, dorsal thighs. | |
•Erythematous, small papules often in occluded areas (eg, skinfolds) •Resolves rapidly | |
•Translucent papules, often with central umbilication •Koebnerization (lesions distributed in linear clusters) often present | |
•Concentrated around mouth, nares, or, less commonly, eyes •Often (but not always) history of preceding use of topical corticosteroids | |
•Typically spares the face. •Potassium hydroxide preparation performed on pustule roof will demonstrate budding yeast. | |
•Lesions have monomorphous appearance (ie, only papules without comedones). •Temporal relationship between onset or worsening of acne and corticosteroid therapy. |
▶The clinical diagnosis of acne vulgaris is usually straightforward.
(Options for acne treatment based on lesion type and disease severity are summarized in Figures 7.5–7.7.)
▶Adolescents are anxious for improvement in their acne, but 4 to 6 weeks or longer may be required to observe a benefit from treatment.
▶Acne treatment is facilitated by optimizing skin care and appropriate pharmacologic intervention tailored to the lesion type and severity of disease.
■Drying of the skin by therapeutic cleansers (eg, those containing salicylic acid) may be aggravated by prescription acne medications containing a retinoid (tretinoin, adapalene, tazarotene), benzoyl peroxide, and some antibiotic formulations. If these prescription products will be used, a mild cleanser should be recommended.
■For those who develop dryness when using acne medications, judicious application of a noncomedogenic moisturizer may be useful.
▶Therapy falls into 4 categories.
■Topical agents: retinoids, benzoyl peroxide, antibiotics, and fixed-dose combination products (Table 7.1), which combine 2 of these agents
■Oral antibiotics: minocycline, doxycycline, sarecycline, tetracycline, erythromycin (latter 2 used less often in the current era); occasionally others
■Hormonal therapy: oral contraceptives, antiand rogens such as spironolactone
▶Treatment strategies are based on lesion type and severity of disease.
■Mild acne (Face: approximately one-fourth of the face is involved; lesions are comedones or a mixture of comedones and few to several papules or pustules; no nodules or scarring.) (see Figure 7.2)
– Topical retinoids or fixed-dose combination products containing a retinoid are ideal for comedonal and mild inflammatory acne, but correct use is essential to minimize problems of irritation. Benzoyl peroxide or fixed-dose combination products containing benzoyl peroxide are an alternative option.
– Retinoid pearls.
•Apply to a dry face.
•Apply no more than a pea-sized amount for the entire face.
1. If the entire face is to be treated, advise the patient to divide the pea-sized aliquot and dab equal amounts on each side of the forehead, each cheek, nose, and chin and then to rub it into the skin.
2. Apply to all involved areas/zones, rather than spot therapy (remember that topical retinoids play a preventive as well as therapeutic role in acne).
•Use a noncomedogenic moisturizer, if needed, to counteract extreme dryness associated with topical retinoid therapy.
■Moderate acne (Face: approximately one-half of the face is involved; there are several to many papules or pustules and a few to several nodules; a few scars may be present.) (see Figures 7.3 and 7.4)
– The initial combination of a retinoid, benzoyl peroxide, and an antibiotic is recommended for the synergy of addressing different aspects of disease pathogenesis. Retinoids are comedolytic and prevent comedogenesis, antibiotics decrease C acnes and reduce inflammation, and benzoyl peroxide—a nonantibiotic antimicrobial—lowers the likelihood of developing antibiotic-resistant C acnes. The ultimate choice of products depends on disease severity, likelihood of patient adherence (fixed-dose combination products may increase adherence), and medication cost/access (brand ed fixed-dose combination products are more expensive).
– Examples of effective topical therapy for moderate acne include
•Fixed-dose topical combination product containing a retinoid and benzoyl peroxide
•Fixed-dose topical combination product containing a retinoid and an antibiotic, along with benzoyl peroxide (in the form of a wash or leave-on product)
•Fixed-dose topical combination product containing benzoyl peroxide and an antibiotic, along with a topical retinoid
•Topical retinoid, antibiotic, and benzoyl peroxide prescribed as individual agents
– Oral antibiotics should be added if significant numbers of inflammatory lesions are present or the chest and back are significantly involved. Again, concomitant use of benzoyl peroxide is recommended because it appears to decrease the risk of developing antibiotic resistance. Systemic antibiotics are not recommended as monotherapy for acne. The duration of oral antibiotic use should be as short as feasible, with consideration for discontinuation at 3- to 6-month intervals.
– Female patients who have significant inflammatory acne, particularly those who have premenstrual or menstrual flares, may benefit from hormonal intervention, such as a combined oral contraceptive or spironolactone.
■Severe acne (Face: approximately three-fourths or more of the face is involved; there are many papules, pustules, cysts, and nodules; scarring often is present.) (Figure 7.8)
– Nodulocystic acne or the presence of scarring warrants prompt consideration for isotretinoin therapy (with referral to a dermatologist).
– High-dose oral antibiotics in combination with topical therapy (eg, benzoyl peroxide and topical retinoid) is an option while considering isotretinoin.
– In female patients, hormonal or antiand rogen therapies can also be considered; however, if they fail and the patient continues to have nodulocystic or scarring lesions, isotretinoin should be strongly considered.
▶Topical retinoids or the combination of topical retinoids and benzoyl peroxide is recommended as maintenance therapy to minimize the likelihood of relapse.
▶Acne vulgaris is often, but not always, self-limited and resolves by the late teenage or early adult years.
▶Treatment is warranted during periods of disease activity to alleviate disfigurement, enhance well-being, and prevent permanent scarring.
▶Management can be challenging because patient expectations are high, efficacy of treatment is variable, and potential medication side effects need to be weighed against benefits, with appropriate matching of therapeutic aggressiveness and severity of disease.
▶Patients require periodic clinical assessments to evaluate response to therapy and provide ongoing support and encouragement.
▶Failure to respond to topical or oral therapies after 2 to 3 months of appropriate use.
▶Severe acne with presence of nodules, cysts, or scarring.
▶Early-onset acne at younger than 7 years (or other signs of and rogen excess) warrants hormonal evaluation.
▶American Academy of Pediatrics: HealthyChildren.org.
▶American Academy of Dermatology: Acne: tips for managing.
https://www.aad.org/public/diseases/acne-and -rosacea/acne
▶MedlinePlus: Information for patients and families (in English and Spanish) sponsored by the US National Library of Medicine and National Institutes of Health.
https://www.nlm.nih.gov/medlineplus/acne.html
▶Society for Pediatric Dermatology: Patient hand out on acne.
https://pedsderm.net/for-patients-families/patient-hand outs/#Anchor-Acne
▶Society for Pediatric Dermatology: Patient hand out on isotretinoin.
https://pedsderm.net/for-patients-families/patient-hand outs/#Isotretinoin
▶WebMD: Information for families is contained in Skin Problems and Treatments.
www.webmd.com/skin-problems-and -treatments/acne/default.htm